Table 2.
The Ranking of Probability by Different Dose Regimens of Glucagon-Like Peptide-1 Receptor Agonists on Gastrointestinal Adverse Events
| Nausea | Vomiting | Diarrhea | ||||
|---|---|---|---|---|---|---|
| Treatment | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank |
| Albi30Q2W | 0.3940 | 17 | 0.3784 | 17 | 0.6488 | 6 |
| Albi30QW | 0.4436 | 13 | 0.5072 | 14 | 0.4848 | 14 |
| Albi50Q2W | 0.8188 | 2 | 0.7652 | 4 | 0.5572 | 10 |
| Albi50QM | 0.5828 | 11 | 0.6076 | 7 | 0.5484 | 11 |
| EX10BID | 0.7144 | 6 | 0.5728 | 9 | 0.5316 | 12 |
| EX2QW | 0.3220 | 18 | 0.3448 | 19 | 0.5732 | 9 |
| EX5BID | 0.3976 | 16 | 0.5164 | 13 | 0.4712 | 15 |
| Insulin | 0.0004 | 26 | 0.0604 | 25 | 0.0644 | 26 |
| LIR0.6QD | 0.4420 | 14 | 0.5372 | 11 | 0.5908 | 8 |
| LIR1.2QD | 0.6132 | 9 | 0.5708 | 10 | 0.7828 | 3 |
| LIR1.8QD | 0.5968 | 10 | 0.5848 | 8 | 0.8072 | 2 |
| LIX20BID | 0.5800 | 12 | 0.6820 | 6 | 0.4328 | 16 |
| LIX20QD | 0.6256 | 8 | 0.5348 | 12 | 0.3480 | 18 |
| LIX30BID | 0.7564 | 5 | 0.4120 | 16 | 0.8476 | 1 |
| LIX30QD | 0.7936 | 3 | 0.8460 | 2 | 0.2504 | 20 |
| LY0.5/1.0 | 0.3056 | 20 | 0.2416 | 20 | 0.2228 | 22 |
| LY1.0/1.0 | 0.4072 | 15 | 0.0312 | 26 | 0.1468 | 23 |
| LY1.0/2.0 | 0.3184 | 19 | 0.4584 | 15 | 0.4864 | 13 |
| Met | 0.1808 | 21 | 0.3484 | 18 | 0.7516 | 4 |
| SU | 0.0744 | 24 | 0.1144 | 23 | 0.2912 | 19 |
| Sitagliptin | 0.0880 | 23 | 0.1808 | 21 | 0.2292 | 21 |
| TAS20Q2W | 0.6948 | 7 | 0.7352 | 5 | 0.6580 | 5 |
| TAS20QW | 0.7928 | 4 | 0.7888 | 3 | 0.3900 | 17 |
| TAS30QW | 0.8320 | 1 | 0.8852 | 1 | 0.5952 | 7 |
| TZD | 0.0368 | 25 | 0.1216 | 22 | 0.0648 | 25 |
| Placebo | 0.1360 | 22 | 0.0848 | 24 | 0.1428 | 24 |
Entries in bold type indicate the first three most harmful treatments on GI AEs.
Albi30Q2W, albiglutide 30 mg once biweekly; Albi30QW, albiglutide 30 mg once weekly; Albi50Q2W, albiglutide 50 mg once biweekly; Albi50QM, albiglutide 50 mg once monthly; EX10BID, exenatide 10 μg twice daily; EX2QW, exenatide 2 mg once weekly; EX5BID, exenatide 5 μg twice daily; LIR0.6QD, liraglutide 0.6 mg once daily; LIR1.2QD, liraglutide 1.2 mg once daily; LIR1.8QD, liraglutide 1.8 mg once daily; LIX20BID, lixisenatide 20 μg twice daily; LIX20QD, lixisenatide 20 μg once daily; LIX30BID, lixisenatide 30 μg twice daily; LIX30QD, lixisenatide 30 μg once daily; LY0.5/1.0, LY2189265 0.5 mg once weekly for 4 weeks, then 1.0 mg once weekly for 12 weeks; LY1.0/1.0, 1.0 mg once weekly for 16 weeks; LY1.0/2.0, 1.0 mg once weekly for 4 weeks, then 2.0 mg once weekly for 12 weeks; Met, metformin; SU, sulfonylureas; SUCRA, surface under the cumulative ranking curve; TAS20Q2W, taspoglutide 20 mg once biweekly; TAS20QW, taspoglutide 20 mg once weekly; TAS30QW, taspoglutide 30 mg once weekly; TZD, thiazolidinedione.